Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24106790 | 0.98 | ALDH1A1 (0.36) | ALDH1A1PKMGAARECQLPOLB | |
| SCHEMBL22455047 | 0.83 | ALDH1A1 (0.30) | ALDH1A1PKM | |
| SCHEMBL25919445 | 0.83 | ALDH1A1 (0.30) | ALDH1A1PKM | |
| SCHEMBL22871678 | 0.83 | CYP2B6 (0.38) | KMT2A | |
| SCHEMBL23336586 | 0.83 | CYP2B6 (0.38) | KMT2A | |
| SCHEMBL21943321 | 0.83 | ALDH1A1 (0.35) | ALDH1A1PKMGAAPOLBL3MBTL1 | |
| SCHEMBL19820306 | 0.83 | ALDH1A1 (0.35) | ALDH1A1PKMGAAPOLBL3MBTL1 | |
| SCHEMBL13813386 | 0.82 | ALDH1A1 (0.38) | ALDH1A1PKMGAAPOLBL3MBTL1 | |
| SCHEMBL21166053 | 0.81 | ALDH1A1 (0.33) | ALDH1A1PKMGAAPOLBMEN1 | |
| SCHEMBL20182443 | 0.80 | CYP2B6 (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | ALDH1A1 4668/4885PKM 1572/4885GAA 809/4885 |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | ALDH1A1 4668/4885PKM 1572/4885GAA 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.